This 2-hour Internet symposium will review and discuss the key studies on chronic hepatitis C management and treatment presented at EASL. This activity has been designed to meet the educational needs of physicians involved in the care of patients with chronic hepatitis C infection. This program is certified for CME credit for US physicians by the Postgraduate Institute for Medicine.
This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HCV infection.
After completing this activity, participants should be able to:
Utilize in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at the 48th EASL;
State the current treatment paradigms for CHC, including the clinical studies and data presented at the 48th EASL, and use that knowledge to improve patient care;
Discuss with patients and colleagues the studies and data on newer therapies for CHC presented at the 48th EASL and use that discussion to decide on appropriate planning of therapy for patients with CHC.
Release Date: May 2, 2013
Expiration Date: May 2, 2014
Estimated time to complete the EASL 2013 Web Symposium: 2 hours
Media: Internet
Mark Sulkowski, MD
Associate Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Nezam H. Afdhal, MD
Professor of Medicine
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center,
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Fred Poordad, MD
Professor of Medicine
University of Texas San Antonio
Chief Medical Officer
Texas Liver Institute
San Antonio, Texas
K. Rajender Reddy, MD
Professor of Medicine
Director of Hepatology
Medical Director of Liver Transplantation
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)TM.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Dr. Mark Sulkowski:Contracted Research: Abbott; BIPI; BMS; Gilead; Janssen; Merck; Roche; Vertex
Consulting Fees: Abbott; BIPI; BMS; Gilead; Janssen; Merck; Novartis; Pfizer; Roche; Vertex
Dr. Nazim Afdhal:
Contracted Research: Schering Plough/Merck; Novartis; GSK; Echosens; Vertex; Gilead; Quest
Consulting Fees: Gilead; Echosens; Biogen; GSK; Vertex; Novartis; Idera Pharmaceuticals; Boehringer Ingelheim; HGS; Biolex; Fibrogen; Ligand; Schering Plough/Merck
Dr. K. Rajender Reddy:
Royalty: Uptodate
Consulting Fees: Contracted Research: Merck; Genentech-Roche; Gilead; Tibotec/Janssen; Vertex
Contracted Research: BMS; Gilead; Vertex; Tibotec/Janssen; Merck; Genentech-Roche; Anadys; Jkaria; Hyperion (Institution receives support)
Dr. Fred Poordad:
Contracted Research: Salix; Vertex; Schering-Plough; Roche; HGS; Novartis; Idenix; Gilead; Abbott; BMS; Zymogenetics; Onyx; Merck
Consulting Fees: Salix; Merck; Genentech; Gilead; Abbott; Vertex; Tibotec
Fees for Non-CME/CE Services Received Directly form a Commercial Interest: Gilead; Genentech; Salix
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
There are no fees for participating and receiving CME credit for this activity. During the period, May 2, 2013 through May 2, 2014, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on www.cmeuniveristy.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 9457. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Supported by an educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
